Definity

(Perflutren)

PreclinicalSmall molecule

LLantheus Medical Imaging

Definity is one of 11 small molecule programs targeting Liver Metastases. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Liver MetastasesCompleted

Renal Blood FlowUnknown status

Liver MetastasesPreclinical

Completed

Renal Blood FlowPreclinical

Unknown status

Competition

Competitive Landscape

11 competitors in Liver Metastases

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 2

9 2

Avastin

Roche

Phase 2

8 3

Camptosar

Pfizer

Phase 2

2 4

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

4 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 2

2 6

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 7

5-Fluorouracil

Merck & Co.

Phase 2

1 8

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 9

Anti-CEA CAR-T Cells

SSorrento Therapeutics, Inc.

Phase 1

4 10

Definity

LLantheus Medical Imaging

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Metastases1 trial

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

Completed·SStanford University·N/A·NCT01631318·34 enrolled

Renal Blood Flow1 trial

Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram

Unknown status·UUniversity of Virginia·N/A·NCT01544036·150 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 31, 2001

DEFINITY

NDA NDA021064

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Perflutren. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perflutren compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perflutren. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021064). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Definity. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Lantheus Medical Imaging company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLantheus Medical Imaging

Patent Landscape[5]

Patent Cliff

Dec 28, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10022460Dec 28, 2035

10583207Dec 28, 2035

11395856Dec 28, 2035

9789210Mar 16, 2037

11857646Mar 16, 2037

6 more patents

11266750Mar 16, 2037

12161730Mar 16, 2037

11529431Mar 16, 2037

10583208Mar 16, 2037

11925695Mar 16, 2037

10588988May 4, 2037

Definity

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Metastases1 trial

Renal Blood Flow1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News